KR20030085941A - Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof - Google Patents
Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof Download PDFInfo
- Publication number
- KR20030085941A KR20030085941A KR1020020024250A KR20020024250A KR20030085941A KR 20030085941 A KR20030085941 A KR 20030085941A KR 1020020024250 A KR1020020024250 A KR 1020020024250A KR 20020024250 A KR20020024250 A KR 20020024250A KR 20030085941 A KR20030085941 A KR 20030085941A
- Authority
- KR
- South Korea
- Prior art keywords
- nanoemulsion
- liposome
- cosmetic composition
- weight
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 69
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 239000002537 cosmetic Substances 0.000 title claims abstract description 52
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 9
- 235000003687 soy isoflavones Nutrition 0.000 title description 3
- 238000009472 formulation Methods 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000006071 cream Substances 0.000 claims description 22
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims description 9
- 229940031578 diisopropyl adipate Drugs 0.000 claims description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 9
- 235000008696 isoflavones Nutrition 0.000 claims description 9
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 8
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 7
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 7
- 239000004359 castor oil Substances 0.000 claims description 7
- 235000019438 castor oil Nutrition 0.000 claims description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 7
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 abstract description 23
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001153 anti-wrinkle effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 102000016942 Elastin Human genes 0.000 description 12
- 108010014258 Elastin Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229920002549 elastin Polymers 0.000 description 12
- 235000016709 nutrition Nutrition 0.000 description 11
- 230000001953 sensory effect Effects 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- -1 lecithin phospholipid Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000979 Erythema Induratum Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 또는 나노에멀젼 및 이를 함유한 화장료 조성물 및 그 제조방법에 관한 것으로, 보다 상세하게는 디팔미토일하이드록시프롤린 및 소이이소플라본을 0.01%∼10% 함유한 리포좀 또는 나노에멀젼을 제조하고, 제조된 리포좀 및/또는 나노에멀젼을 0.1∼20%의 양으로 화장료에 첨가하여 제조한 화장료 조성물로서, 리포좀과 나노에멀젼 구조는 유효성분인 디팔미토일하이드록시프롤린과 소이이소플라본의 피부투과를 촉진시키고 지속적인 방출을 가능하게 하므로 이를 함유한 화장료 조성물은 피부 보습력과 피부주름의 생성억제력이 우수한 특징이 있다.The present invention relates to liposomes or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones, and to cosmetic compositions containing the same, and more specifically to dipalmitoylhydroxyproline and soisoisoflavones. A cosmetic composition prepared by preparing liposomes or nanoemulsions containing% to 10%, and adding the prepared liposomes and / or nanoemulsions to the cosmetics in an amount of 0.1 to 20%, wherein the liposomes and nanoemulsion structures are active ingredients. Since it promotes skin permeation and sustained release of palmitoylhydroxyproline and soisoisoflavones, the cosmetic composition containing the same has excellent skin moisturizing power and anti-wrinkle production.
Description
본 발명은 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 또는 나노에멀젼 및 그를 함유한 화장료 조성물에 관한 것으로, 보다 상세하게는 디팔미토일하이드록시프롤린 및 소이이소플라본을 레시틴 인지질 소낭에 봉입(encapsulation)하여 피부투과성과 지속성이 우수한 리포좀 또는 나노에멀젼을 만들고, 이를 함유하여 제조된 피부보습 및 탄력유지에 우수한 화장료 조성물에 관한 것이다.The present invention relates to liposomes or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones and cosmetic compositions containing them, and more particularly, dipalmitoylhydroxyproline and soisoisoflavones are encapsulated in lecithin phospholipid vesicles. (encapsulation) to create a liposome or nanoemulsion having excellent skin permeability and durability, and relates to a cosmetic composition excellent in skin moisturizing and elasticity prepared by containing it.
나이가 들어감에 따라 피부의 탄력이 떨어지고 수분보유량이 손실됨으로서 초래되는 피부주름과 피부건조화 등의 노화현상을 억제하는 방법은 화장료의 가장 큰 관심분야 중 하나이다.The method of suppressing the aging phenomenon such as skin wrinkles and skin drying caused by the decrease of elasticity of the skin and loss of moisture retention with age is one of the biggest areas of interest in cosmetics.
이러한 피부의 노화현상은 여러 가지 원인에 의해 초래되지만, 가장 중요한 요인은 진피분해, 즉 피부활성을 상실하게 하는 피부 깊숙한 곳에서의 구조적인 변화이다. 진피세포조직이 분해됨으로써 피부표면은 그 본래의 탄탄함을 잃고 점차 느슨해지는 것이다.The aging of the skin is caused by various causes, but the most important factor is the structural change deep in the skin, which leads to dermal degradation, that is, the loss of skin activity. As the dermal tissue breaks down, the skin surface loses its original firmness and gradually loosens.
진피세포는 표피의 바로 아래에 위치하며 매우 민감한 층으로 콜라겐 섬유소가 그물모양으로 짜여 있고, 그 사이사이에 엘라스틴 섬유소가 스프링처럼 얽혀서 피부의 탄력을 유지하고 있다. 이 그물구조가 일정하게 잘 짜여 있으면 피부는 탄력있고 매끈한 상태를 유지하지만, 콜라겐과 엘라스틴의 그물구조가 파괴되면 피부는 탄력을 잃는다.Dermal cells are located just below the epidermis and are a very sensitive layer of collagen fibers that are woven into a net-like shape, between which elastin fibers are entangled like springs to maintain the elasticity of the skin. If the net structure is consistently well-woven, the skin will remain elastic and smooth, but if the net structure of collagen and elastin is broken, the skin will lose its elasticity.
콜라겐과 엘라스틴은 섬유아세포(fibroblast)에서 합성되며, 섬유아세포의 활동상태가 콜라겐이나 엘라스틴의 상태에 중요한 영향을 미친다. 그러나 나이가 들어감에 따라 섬유아세포의 활성이 저하되어 콜라겐과 엘라스틴의 합성능이 현저히 저하되고, 이로 인해 피부의 탄력이 떨어진다.Collagen and elastin are synthesized in fibroblasts, and the activity of fibroblasts has an important effect on the state of collagen and elastin. However, with age, the activity of fibroblasts decreases, which significantly reduces the synthesis of collagen and elastin, thereby reducing the elasticity of the skin.
따라서 종래에는 진피층의 콜라겐과 엘라스틴을 유지하여 피부노화를 저지시킬 목적으로 화장료에 직접 콜라겐과 엘라스틴을 균일하게 혼합시키거나 화장료용 캡슐로 제조하여 화장료에 분산시키는 방법이 사용되어 왔다. 그러나 피부에 도포된 콜라겐과 엘라스틴이 실질적으로 효과를 나타내기 위해서는 진피층까지 침투해야 하는데 종래의 방법으로는 콜라겐과 엘라스틴의 진피층 흡수률이 낮고 지속적으로 작용하게 하는데 어려움이 있었다.Therefore, conventionally, a method of uniformly mixing collagen and elastin directly into a cosmetic or preparing a cosmetic capsule and dispersing it in cosmetics has been used for the purpose of preventing skin aging by maintaining collagen and elastin in the dermal layer. However, collagen and elastin applied to the skin have to penetrate into the dermis layer in order to have a practical effect. However, in the conventional method, collagen and elastin have a low rate of absorption of the dermis and continue to operate continuously.
본 발명은 상기 문제점을 해결하기 위하여 콜라겐과 엘라스틴의 생성과 안정화에 유효한 디팔미토일하이드록시프롤린과 소이이소플라빈을 리포좀 또는 나노에멀젼에 봉입하고 이를 화장료에 함유하여 피부의 보습 및 탄력유지에 유효한 화장료 조성물을 제공하는 것을 목적으로 한다.In order to solve the above problems, dipalmitoylhydroxyproline and soisoflavin, which are effective for the production and stabilization of collagen and elastin, are encapsulated in liposomes or nanoemulsions and are contained in cosmetics, which are effective for moisturizing and maintaining elasticity of skin. It is an object to provide a cosmetic composition.
따라서 본 발명의 목적은 피부의 보습 및 탄력유지를 위해 필수적인 콜라겐과 엘라스틴의 생성·유지에 유효한 상기 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀과 나노에멀젼을 제공하는 것이다.Accordingly, it is an object of the present invention to provide liposomes and nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones effective for the production and maintenance of collagen and elastin, which are essential for moisturizing and maintaining elasticity of skin.
또한 본 발명의 또 다른 목적은 상기 리포좀 및/또는 나노에멀젼을 함유한 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a cosmetic composition containing the liposomes and / or nanoemulsions.
상기 목적을 달성하기 위해 본 발명에 따른 리포좀 또는 나노에멀젼은 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유하는 것을 특징으로 한다.In order to achieve the above object, liposomes or nanoemulsions according to the present invention are characterized by containing dipalmitoylhydroxyproline and soisoisoflavones.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명에 따른 리포좀 및/또는 나노에멀젼을 함유한 화장료 조성물은, 0.01∼20.0중량%의 리포좀 및/또는 나노에멀젼과 80∼99.99%의 화장료 성분이 배합된 것으로서, 바람직하게는 0.1∼10.0중량%의 리포좀 또는 나노에멀젼에 90∼99.9중량%의 화장료 성분이 배합되는 것을 특징으로 한다.In order to achieve another object of the present invention, the cosmetic composition containing liposomes and / or nanoemulsions according to the present invention comprises a blend of 0.01 to 20.0% by weight of liposomes and / or nanoemulsions and 80 to 99.99% of cosmetic components. Preferably, 0.1 to 10.0% by weight of liposomes or nanoemulsions are blended with 90 to 99.9% by weight of cosmetic components.
본 발명의 또 다른 목적을 달성하기 위하여 본 발명에 따른 화장료 조성물의 제조방법은 디팔미토일하이드록시프롤린, 카프릴릭/카프릭 트리글리세리드 및 디이소프로필아디페이트를 가온하여 혼합용해한 후 냉각시키는 단계;In order to achieve the another object of the present invention, the method for preparing a cosmetic composition according to the present invention comprises the steps of dissolving and dissolving dipalmitoylhydroxyproline, caprylic / capric triglyceride and diisopropyl adipate, followed by heating;
여기에 가용화제로서 피이지 40 하이드로제네이티드 캐스터오일을 혼합하고 불포화레시틴, 소이이소플라본(아글리콘), 글리세롤, 알콜을 혼합한 후, 정제수를 추가하는 단계;Mixing PIG 40 hydrogenated castor oil as a solubilizing agent and mixing unsaturated lecithin, soisoisoflavone (aglycone), glycerol, and alcohol, followed by adding purified water;
혼합된 용액을 고압유화장치(Microfluidizer)에 통과시키는 단계를 포함하는 것을 특징으로 한다.Passing the mixed solution through a high pressure emulsifier (Microfluidizer) is characterized in that it comprises.
도1은 본 발명에 의해 제조된 리포좀과 나노에멀젼의 입자크기 및 분포를 측정하여 도시한 것이다.Figure 1 shows the measured particle size and distribution of the liposomes and nanoemulsion prepared by the present invention.
이하 본 발명에 대해 상세히 설명하기로 한다.Hereinafter, the present invention will be described in detail.
하이드록시프롤린은 분자주위에 물분자를 단단히 결합시킬 수 있어 보습력이 우수하다. 또한 엘라스틴분해효소인 엘라스타제의 과잉생성을 억제하고, 콜라겐의 3중나선구조를 안정화하는데 중요한 화합물로서 콜라겐 형성에 필수적이다.디팔미토일하이드록시프롤린은 하이드록시프롤린에 지방산의 일종인 팔미틴산을 결합한 화합물로서 피부투과성이 우수하여 하이드록시프롤린의 피부흡수를 용이하게 하고, 아울러 친유형 구조를 가지므로 피부외층에서의 수분손실을 막아준다.Hydroxyproline is excellent in moisturizing ability because it can firmly bind water molecules around molecules. In addition, it is essential for collagen formation as an important compound for inhibiting the overproduction of elastinase and stabilizing the triple helix structure of collagen. Dipalmitoylhydroxyproline is used to convert palmitic acid, a type of fatty acid, to hydroxyproline. As a combined compound, it has excellent skin permeability and facilitates skin absorption of hydroxyproline, and also has a lipophilic structure, thereby preventing water loss in the outer skin layer.
소이이소플라본은 여성의 성호르몬인 에스트로겐(estrogen)의 수용체에 결합하여 에스트로겐과 유사한 기능을 한다. 에스트로겐은 콜라겐과 엘라스틴의 생성을 자극한다. 에스트로겐을 갱년기 이후의 여성에게 투여한 결과 콜라겐의 양, 피부탄성력 및 피부두께가 증가하였다. 그러나 이러한 호르몬 대체요법은 심장병과 자궁암을 유발하는 부작용이 있다. 그러나 소이이소플라빈은 부작용이 없는 식물성 에스트로겐으로서 소이이소플라빈을 다량 함유한 대두 식품이 갱년기 여성의 골다공증, 자궁암, 유방암 예방에 유효함은 널리 알려져 있다.Soy isoflavones bind to the receptors of the female sex hormone estrogen and function similar to estrogen. Estrogens stimulate the production of collagen and elastin. Administration of estrogen to postmenopausal women increased the amount of collagen, skin elasticity and skin thickness. However, these hormone replacement therapies have side effects that cause heart disease and uterine cancer. However, it is widely known that soy isoflavin is a phytoestrogens with no side effects, and soy foods containing large amounts of soy isoflavin are effective for preventing osteoporosis, uterine cancer and breast cancer in menopausal women.
이소플라본은 당이 붙은 배당체 형태와 당이 분리된 비배당체 형태의 크게 두 가지 부류로 나눌 수 있는데, 배당체는 피부를 통과할 수 없기 때문에 화장료에는 당을 제거한 아글리콘(aglycone) 타입이 사용된다.Isoflavones can be divided into two broad classes: sugar-containing glycosides and sugar-free glycosides. Since glycosides cannot penetrate the skin, sugar-free aglycone types are used in cosmetics.
본 발명은 전술한 디팔미토일하이드록시프롤린 및 소이이소플라본의 기능에 주목하여 디팔미토일하이드록시프롤린과 소이이소플라본을 화장품에 함유시키고, 이를 피부에 유효하게 침투시키는 수단에 대하여 집중적으로 연구하였다.The present invention focused on the functions of dipalmitoylhydroxyproline and soisoisoflavones described above, and focused on the means for containing dipalmitoylhydroxyproline and soisoisoflavones in cosmetics and effectively infiltrating them into the skin. .
지금까지 알려진 바에 따르면 화장료 조성에서 수분과 유효생리활성성분을 효과적으로 피부에 침투시키기에 가장 적합한 구조는 리포좀과 나노에멀젼이다.As far as is known, the most suitable structures for penetrating moisture and effective bioactive ingredients into the skin in cosmetic compositions are liposomes and nanoemulsions.
리포좀과 나노에멀젼은 그 구조상 피부조직과 친화력이 우수하고 친수성 물질과 친유성 물질을 모두 함유할 수 있으며 함유물질을 서서히 지속적으로 방출하도록 조절할 수 있기 때문이다.It is because liposomes and nanoemulsions have excellent affinity with skin tissues, they can contain both hydrophilic and lipophilic substances, and can be controlled to release their contents slowly and continuously.
리포좀이란 자기 스스로 회합하는 콜로이드 입자들의 구형 인지질 소낭(vesicle)으로서, 친수성 헤드와 친유성 테일의 양친매성 분자의 상호작용에 의하여 자발적으로 정렬된 구조를 만든다. 약물전달에 사용되는 리포좀은 일반적으로 밀폐형의 이중막(bilayer) 구조로서 수용성 핵 내부에 친수성 물질을 함유할 수 있고, 양친매성 물질 또는 친유성 물질들을 지질 이중층 내부에 함유할 수 있다.Liposomes are spherical phospholipid vesicles of self-associating colloidal particles that form spontaneously aligned structures by the interaction of the amphiphilic molecules of the hydrophilic head and the lipophilic tail. Liposomes used for drug delivery are generally closed bilayer structures, which may contain a hydrophilic material inside the water-soluble nucleus, and may contain amphiphilic or lipophilic materials inside the lipid bilayer.
나노에멀젼이란 인지질의 단분자층에 의해 형성되는 입자의 평균직경이 30∼1,000nm인 소낭으로서 물속에 기름이 분산된 O/W형은 내부에 지용성핵을 가진다.Nanoemulsion is a vesicle with an average diameter of 30-1,000 nm of particles formed by a monomolecular layer of phospholipid. O / W type in which oil is dispersed in water has a fat-soluble core inside.
본 발명은 리포좀과 나노에멀젼의 인지질 막의 형성에 불포화레시틴을 사용한다. 불포화레시틴은 각질층을 유화시켜 소수성분자의 피부투과를 촉진한다.The present invention uses unsaturated lecithin to form phospholipid membranes of liposomes and nanoemulsions. Unsaturated lecithin emulsifies the stratum corneum and promotes skin penetration of minor components.
또한 본 발명의 리포좀과 나노에멀젼은 에스테르 화합물인 디이소프로필아디페이트를 함유한다. 디이소프로필아디페이트는 디팔미토일하이드록시프롤린을 용해하여 리포좀 또는 나노에멀젼 내에서 안정한 상태로 만들어 주므로 리포좀 또는 나노에멀젼의 안정화에 유효하다.In addition, the liposomes and nanoemulsions of the present invention contain diisopropyl adipate, which is an ester compound. Diisopropyl adipate is effective for stabilizing liposomes or nanoemulsions by dissolving dipalmitoylhydroxyproline to make them stable in liposomes or nanoemulsions.
본 발명에 따른 리포좀 또는 나노에멀젼은 디팔미토일하이드록시프롤린 및 소이이소플라본을 0.01∼10중량%로 함유한다.Liposomes or nanoemulsions according to the present invention contain dipalmitoylhydroxyproline and isoisoflavones in an amount of 0.01 to 10% by weight.
또한 본 발명에 따른 리포좀 또는 나노에멀젼은 리포좀 또는 나노에멀젼 총중량에 대하여 1∼5중량%이 레시틴 및 1∼5중량%의 가용화제가 함유되고, 카프릴릭/카프릭트리글리세리드, 글리세롤, 알콜이 20∼50중량%로 혼합된다.In addition, liposomes or nanoemulsions according to the present invention contain 1 to 5% by weight of lecithin and 1 to 5% by weight of a solubilizing agent with respect to the total weight of liposomes or nanoemulsions, and 20 to 5 to caprylic / capric triglycerides, glycerol, alcohols. 50% by weight is mixed.
본 발명에 따른 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 및/또는 나노에멀젼을 함유한 화장료 조성물은, 0.01∼20.0중량%의 리포좀 및/또는 나노에멀젼과 80∼99.99%의 화장료 성분이 배합된 것으로서, 바람직하게는 0.1∼10.0중량%의 리포좀 또는 나노에멀젼에 90∼99.9중량%의 화장료 성분이 배합된 것이다.Cosmetic compositions containing liposomes and / or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones according to the present invention comprise 0.01 to 20.0% by weight liposomes and / or nanoemulsions and 80 to 99.99% cosmetic ingredients. As this compound, 90 to 99.9% by weight of the cosmetic component is preferably blended with 0.1 to 10.0% by weight of liposomes or nanoemulsions.
다음에 구체적인 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 및 나노에멀젼의 제조예 및 이 리포좀과 나노에멀젼을 함유하는 화장료의 제형예를 들어 본 발명을 상세히 설명한다. 그러나 본 발명이 이에 한정되는 것은 아니다.Next, the present invention will be described in detail with examples of preparation of liposomes and nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones, and formulation examples of cosmetics containing the liposomes and nanoemulsions. However, the present invention is not limited thereto.
실시예1Example 1
리포좀 및/또는 나노에멀젼의 제조방법Method for preparing liposomes and / or nanoemulsions
리포좀 또는 나노에멀젼의 제조에는 고압유화장치(microfluidizer)를 사용하는 공지의 고압균질혼합방법(high pressure homogenization)이 사용된다.In the preparation of liposomes or nanoemulsions, known high pressure homogenization using a microfluidizer is used.
구체적인 제조예는 다음과 같다.Specific manufacturing examples are as follows.
먼저, 하기 표1과 같은 조성으로 디팔미토일하이드록시프롤린 0.5 중량%, 카프릴릭/카프릭 트리글리세리드 8.0중량% 및 디이소프로필아디페이트 1.0중량%를 70℃까지 가온하여 혼합용해한 후 냉각시켰다. 여기에 가용화제로서 피이지 40 하이드로제네이티드 캐스터오일 2.0중량%를 혼합하고 불포화레시틴 5.0중량%, 소이이소플라본(아글리콘) 0.06중량%, 글리세롤 15.0중량, 알콜 15.0중량%를 혼합한 후, 정제수를 추가하여 중량 100%로 만들었다. 혼합된 용액을 1,200bar의 압력조건하에서 고압유화장치(Microfluidizer)에 5회 통과시켜 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀 및 나노에멀젼을 얻었다.First, 0.5% by weight of dipalmitoylhydroxyproline, 8.0% by weight of caprylic / capric triglyceride, and 1.0% by weight of diisopropyl adipate were mixed and dissolved in a composition as shown in Table 1, followed by cooling. To this, 2.0% by weight of Fiji 40 Hydrogenated Castor Oil was mixed as a solubilizing agent, 5.0% by weight of unsaturated lecithin, 0.06% by weight of isoflavone (aglycone), 15.0% by weight of glycerol, and 15.0% by weight of alcohol. Was added to make the weight 100%. The mixed solution was passed through a high pressure emulsifier (Microfluidizer) five times under a pressure of 1,200 bar to obtain liposomes and nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones.
[표1]리포좀과 나노에멀젼의 성분Table 1: Liposomes and Nanoemulsion Components
상기 제조예1에 의해 제조된 리포좀과 나노에멀젼을 25℃ 항온조에 보관 후 레이저광산란시스템(Laser light scattering system)인 Autosizer Lo-C MALVERN. UK을 이용하여 입자의 분포와 크기를 측정한 후 이를 도1에 도시하였다.After storing the liposomes and nanoemulsion prepared in Preparation Example 1 in a 25 ℃ thermostat, Autosizer Lo-C MALVERN of a laser light scattering system (Laser light scattering system). The distribution and size of the particles were measured using the UK and shown in FIG. 1.
본 발명에 의해 제조된 리포좀 또는 나노에멀젼의 크기는 30∼130nm이며, 평균 크기가 51.6nm의 미세한 입자로서 피부침투력이 우수하였다.The size of liposomes or nanoemulsions prepared by the present invention is 30 ~ 130nm, the average size is 51.6nm fine particles with excellent skin penetration.
-제형예-Formulation Example
이하 제형예를 들어 상기 실시예1에서 제조된 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀 및/또는 나노에멀젼을 함유하는 화장료의 구성을 보다 구체적으로 설명한다. 그러나 본 발명은 다음의 영양크림, 영양화장수,유연화장수의 제형예에 한정되는 것은 아니고, 수렴화장수, 아이크림, 맛사지크림, 클린싱크림, 클린징폼, 클린싱 워터, 팩 등의 제형으로도 가능하다.Hereinafter, the configuration of the cosmetics containing the liposomes and / or nanoemulsions containing the dipalmitoylhydroxyproline and the isoflavone prepared in Example 1 will be described in more detail. However, the present invention is not limited to the following formulations of nutrition cream, nourishing cosmetics, and soft cosmetics, and can also be formulated into astringent cosmetics, eye cream, massage cream, cleansing cream, cleansing foam, cleansing water, pack and the like.
제형예 1Formulation Example 1
영양크림의 제조Preparation of Nutritional Cream
하기 표2의 조성으로 보습성분인 A상을 75℃까지 가온하고 일정속도로 교반하고, 피부표면에 보호유막을 제공하는 B상을 70℃까지 가온하고 일정속도로 교반한 후 B상을 A상에 서서히 투입하면서 유화시켰다. C상을 (A+B)에 투입한 후 서서히 냉각, 여과한 후 숙성하여 용기에 충전하였다.In the composition of Table 2, phase A, which is a moisturizing component, is heated to 75 ° C. and stirred at a constant speed, phase B which provides a protective oil film on the skin surface is heated to 70 ° C., stirred at a constant speed, and phase B is phase A It was emulsified while slowly added to. Phase C was added to (A + B), then slowly cooled, filtered and aged to fill the vessel.
[표 2] 영양크림의 제형예 및 비교예TABLE 2 Formulation Examples and Comparative Examples of Nutritional Cream
제형예 2Formulation Example 2
영양화장수의 제조Preparation of Nutrients
하기 표3의 조성으로 보습성분인 A상을 75℃까지 가온하고 일정속도로 교반하고, 피부표면에 보호유막을 제공하는 B상을 70℃까지 가온하고 일정속도로 교반한 후 B상을 A상에 서서히 투입하면서 유화시켰다. C상을 (A+B)에 투입한 후 서서히 냉각, 여과한 후 숙성하여 용기에 충전하였다.In the composition shown in Table 3, phase A, which is a moisturizing component, is heated to 75 ° C. and stirred at a constant speed, phase B which provides a protective oil film on the skin surface is heated to 70 ° C., stirred at a constant speed, and phase B is phase A It was emulsified while slowly added to. Phase C was added to (A + B), then slowly cooled, filtered and aged to fill the vessel.
[표 3] 영양화장수의 제형예 및 비교예Table 3 Formulation Examples and Comparative Examples of Nutrients
제형예 3Formulation Example 3
유연화장수의 제조방법Manufacturing method of flexible cosmetics
하기 표4의 조성으로 A, B, C, D를 차례대로 넣고, 일정속도로 교반하여 혼합한다.A, B, C, D are sequentially added to the composition shown in Table 4 below, followed by stirring at a constant speed to mix.
[표 4] 유연화장수의 제형예 및 비교예Table 4 Formulation Examples and Comparative Examples of Softener
-본 발명에 따른 화장료의 효능조사시험--Efficacy investigation test of the cosmetics according to the present invention-
상기 3가지 제형예 및 비교예에 따라 제조한 내용물 각각에 대하여 보습능 및 일반관능시험을 25-45세의 여성 10명을 대상으로 기기측정 및 비교품평을 실시하였다.For each of the contents prepared according to the three formulation examples and comparative examples, the measurement and comparative evaluation of the moisturizing ability and general sensory test for 10 women aged 25-45 years.
[시험예 1] 보습효과시험[Test Example 1] Moisturizing effect test
상기 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀과 나노에멀젼을 함유한 화장료에 대한 피부보습 효과를 측정하였다.The skin moisturizing effect of the liposomes containing the dipalmitoylhydroxyproline and the isoflavone and the cosmetics containing the nanoemulsion were measured.
25℃, 상대습도 45%, 공기의 흐름이 없는 실내에서, 건강한 여성 10명을 오른쪽, 왼쪽 전주와 하방 5cm 되는 위치에 오른쪽을 대상으로는 실시예를, 왼쪽을 대상으로는 비교실시예를 상기 표 1에 따라 제형하여 팔의 전주와 하방 5cm되는 위치에 1일 2회 7일간 도포한 후 Corneometer CM 825 (CK Courage & KhazakaGermany)를 이용하여 표피 수분량에 따른 전기전도도의 변화로 0에서 150까지 피부의 수분량을 수치화하여 피부에서 수분량을 5회 연속 측정하여 평균값을 측정치로 보습효과를 측정하였다. 실험결과는 하기 표5에 나타내었다.In a room without air flow at 25 ° C., relative humidity of 45%, 10 healthy women were placed on the right, left poles, and 5 cm below, with the examples on the right and the comparative examples on the left. Formulated according to Table 1 and applied twice a day for 7 days at the position of 5cm below the forearm and the lower arm of the arm, using Corneometer CM 825 (CK Courage & KhazakaGermany) to change the electrical conductivity according to the epidermal moisture content from 0 to 150 Moisturizing effect was quantified by measuring the moisture content in the skin five times in a row and the average value was measured as a moisturizing effect. The experimental results are shown in Table 5 below.
[표 5] 피부보습효과[Table 5] Skin moisturizing effect
시험결과, 본 발명의 실시예는 1회 사용직후 42, 2일 사용후 58, 4일 사용후 68, 7일 사용후 75의 수분량이 평균측정되어, 비교실시예와 비교하여 보다 향상된 효과를 나타내었으며, 지속적으로 사용할수록 비교실시예의 화장료에 비해 더욱 뚜렷한 보습능 증대의 효과를 보였다.As a result of the test, the Examples of the present invention were measured immediately after the first use of 42, after 2 days of use 58, after 4 days of 68, 7 days after 75 days of use, the average amount of water was measured, showing an improved effect compared to the Comparative Example As it is used continuously, the effect of increasing the moisturizing effect was more pronounced compared to the cosmetic of the comparative example.
[시험예 2] 피부 안전성 실험Test Example 2 Skin Safety Experiment
상기 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 및/또는 나노에멀젼을 함유한 화장료에 대한 피부 안전성 실험을 실시하였다.Skin safety experiments were carried out on cosmetics containing liposomes and / or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones.
피검자 10명(연령분포 25세-45세)을 Haye's Test Chamber를 이용하여 상박에 피부 첩포시험(Patch Test)을 실시하였다. 단 건선(Psoriasis), 습진(Eczema), 기타 피부병변 보유자나 임신, 수유부 또는 피임제, 항히스타민제 등을 복용하고 있는 사람은 본 실험에서 제외하였다.Ten subjects (age distribution 25-45 years old) were subjected to a patch test on the upper arm using Haye's Test Chamber. Psoriasis, eczema, and other skin lesion holders, or those who are pregnant, nursing or contraceptives, and antihistamines, were excluded from this study.
시험부위를 70% 에탄올로 닦아낸 뒤 건조시킨 다음, 상기 표 3에 따라 실시예와 비교실시예를 제형하여 각각 15㎍씩 Chamber에 적하 시킨 후 시험 부위인 상박 부위에 얹어 고정시킨다. 24시간 동안 도포하여 첩포를 제거한 후에는 마킹펜으로 시험부위를 표시하여 각각 24시간, 48시간 후에 시험부위를 관찰한다. 판정은 첩포 제거 24시간, 48시간 후에 행하며 피부반응은 하기 표 6의 국제접촉피부염연구회(International Contact Dermatitis Research Group:ICDRG)의 규정에 따라 판정하였다. 실험결과는 하기 표 7에 나타내었다.After wiping the test site with 70% ethanol and drying, the sample and the comparative example were formulated according to the above Table 3 and dropped into the chamber by 15 µg, respectively, and then fixed on the upper arm, which is the test site. After removing the patch by applying for 24 hours, mark the test site with a marking pen and observe the test site after 24 hours and 48 hours, respectively. Determination is carried out 24 hours and 48 hours after patch removal. The judgment was made according to the regulations of the International Contact Dermatitis Research Group (ICDRG) of Table 6. The experimental results are shown in Table 7 below.
[표 6] 국제접촉피부염연구회의 판정 기준[Table 6] Judgment Criteria for International Contact Dermatitis Research Group
[표 7] 피부 안전성Table 7 Skin Safety
피부 안전성 실험결과 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 및/또는 나노에멀젼을 함유한 영양크림(제형예1)은 평균 자극정도가 0으로 피검자 전원에서 자극을 보이지 않아 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀과 나노에멀젼이 피부에 자극이 없는 안전한 물질임을 알 수 있다.As a result of skin safety test, liposomes containing dipalmitoylhydroxyproline and soisoisoflavones and / or nutritional creams containing nanoemulsions (Formulation Example 1) did not show irritation in all the subjects with an average irritation degree of 0 It can be seen that liposomes and nanoemulsions containing hydroxyproline and soisoisoflavones are safe substances without irritation to the skin.
[시험예 3] 보습 효과 관능 시험[Test Example 3] Moisturizing effect sensory test
전술한 제형예 및 비교예에 따라 제조한 영양크림, 영양화장수, 유연화장수에 대해 보습효과를 25∼45세의 여성 10명을 대상으로 1일 2회 7일간 사용후 5점 척도 비교 품평하였다. 피부 보습이 향상 되었는가라는 질문에 대해 '전혀 그렇지 않다-1점', '그렇지 않다-2점', '보통이다-3점' , '그렇다-4점' , '매우 그렇다-5점'으로 품평하도록 하였고, 적용시점은 제품의 1회 사용직후와 1일 2회 7일 사용후로 나누어 비교 품평하였다. 그 결과는 표8에 나타나 있다.The moisturizing effect of the nutritional cream, the nourishing cosmetics, and the softening cosmetics prepared according to the above-described formulation examples and comparative examples was compared and evaluated five-point scales after 10 days of use for 10 women aged 25 to 45 years. Regarding the question of whether skin moisturization has improved, it is criticized as 'not at all-1', 'not at most-2', 'normal is-3', 'yes-4' and 'very yes-5' The point of application was comparatively divided into just after using the product once and after using it twice a day for 7 days. The results are shown in Table 8.
[표 8] 본 발명의 비교 관능 데이터(피부 보습 효과)Table 8 Comparative sensory data of the present invention (skin moisturizing effect)
[시험예 4] 탄력 효과 관능 시험Test Example 4 Elasticity Sensory Test
전술한 제형예 및 비교예에 따라 제조한 영양크림, 영양화장수, 유연화장수에 대해 탄력효과를 25∼45세의 여성 10명을 대상으로 1일 2회 7일간 사용후 5점 척도 비교 품평하였다. 피부 탄력이 향상되었는가라는 질문에 대해 '전혀 그렇지 않다-1점', '그렇지 않다-2점', '보통이다-3점' , '그렇다-4점' , '매우 그렇다-5점'으로 품평하도록 하였고, 적용시점은 제품의 1회 사용직후와 1일 2회 7일 사용후로 나누어 비교 품평하였다. 그 결과는 표9에 나타나 있다.The elasticity effect on the nutrition cream, nourishing cosmetics, and supple cosmetics prepared according to the above-described formulation examples and comparative examples was compared and evaluated five-point scale after use twice a day for 10 women aged 25 to 45 years. Regarding the question of whether skin elasticity has improved, it is criticized as 'not at all-1', 'not at most-2', 'normal is-3', 'yes-4' and 'very yes-5'. The point of application was comparatively divided into just after using the product once and 7 days after using it twice a day. The results are shown in Table 9.
[표 9] 본 발명의 비교 관능 데이터(탄력 증가 효과)Table 9 Comparative sensory data of the present invention (elasticity increasing effect)
[표 8, 9]은 피험자가 직접 사용해 보고 감각(관능)으로 인지한 제품효과를 평가한 것이다. 이와같이, 피험자의 감각(관능)으로 평가한 숫치는 5점 만점으로하여 10명의 평균을 내어 수치화하였다. 피험자들이 평가한 수치는 높을수록 만족도가 높은 제품으로, 만족도는 곧 제품이 우수함을 말해준다 할 것이다.Tables 8 and 9 evaluate the product effects perceived by the subject and perceived by sensory (sensation). Thus, the numerical value evaluated by the sensory (sensation) of the subject was digitized by taking the average of 10 points out of 5 points. The higher the value of the subjects was, the higher the satisfaction was, and the satisfaction would soon indicate that the product was excellent.
본 발명의 제형예 1에 의해 제조된 영양크림을 예로 들어 설명하면, 제형예1에 의해 제조된 영양크림은 보습효능에 대한 관능평가가 1회 사용직후 및 1일 2회 7일 사용후가 각각 3.9 및 4.5로서 비교제형예1에 의해 제조된 영양크림의 보습효능에 대한 관능평가 3.8 및 4.2에 비해 지속적인 사용에 의해 우수한 효과를 얻을 수 있었다.For example, the nutrition cream prepared by Formulation Example 1 of the present invention, the nutrition cream prepared by Formulation Example 1 is a sensory evaluation on the moisturizing efficacy immediately after one use and twice a day after 7 days of use, respectively As 3.9 and 4.5, excellent effects were obtained by continuous use compared to sensory evaluation 3.8 and 4.2 for the moisturizing effect of the nourishing cream prepared by Comparative Formulation Example 1.
탄력증가에 대한 관능평가는 비교예1의 영양크림은 1회 사용직후 및 1일 2회 7일 사용후가 각각 3.1 및 3.3임에 비해, 제형예1의 영양크림은 각각 3.2 및 4.2여서 본 발명의 디팔미토일하이드록시프롤린 및 소이이소플라본을 함유한 리포좀 및/또는 나노에멀젼을 함유한 화장료는 피부보습능력 및 탄력증가효과에 있어서, 우수한 효과가 있음을 알 수 있다.The sensory evaluation of the increase in elasticity is that the nutrition cream of Comparative Example 1 is 3.1 and 3.3, respectively, immediately after one use and twice a day after 7 days of use. It can be seen that the cosmetics containing liposomes and / or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones have excellent effects on skin moisturizing ability and elasticity increasing effect.
이상 설명한 바와 같이 디팔미토일하이드록시프롤린과 소이이소플라본을 함유한 리포좀 또는 나노에멀젼 및 이를 함유한 화장료는 보습효과, 탄력증가 및 일반관능사용성에서 통상적인 비교제형예에 비교해 보다 향상된 효과를 보였으며, 특히 지속적으로 사용하는 경우 보다 우수한 효과를 나타내었다.As described above, liposomes or nanoemulsions containing dipalmitoylhydroxyproline and soisoisoflavones and cosmetics containing them showed more improved effects in moisturizing effect, increased elasticity and general functional usability compared to conventional comparative formulations. In particular, it showed a better effect when used continuously.
이와 같이 본 발명은 피부에 효과적으로 작용하여 피부의 보습능력 및 탄력을 증가시켜 탄력있고 건강한 피부를 유지하는데 유효하다.As such, the present invention is effective to maintain elastic and healthy skin by effectively acting on the skin to increase the moisturizing ability and elasticity of the skin.
Claims (29)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0024250A KR100482355B1 (en) | 2002-05-02 | 2002-05-02 | Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0024250A KR100482355B1 (en) | 2002-05-02 | 2002-05-02 | Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030085941A true KR20030085941A (en) | 2003-11-07 |
| KR100482355B1 KR100482355B1 (en) | 2005-04-14 |
Family
ID=32381312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2002-0024250A Expired - Lifetime KR100482355B1 (en) | 2002-05-02 | 2002-05-02 | Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100482355B1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2894828A1 (en) * | 2005-12-21 | 2007-06-22 | Jean Alexis Grimaud | NEW COSMETOLOGICAL AND / OR DERMATOLOGICAL COMPOSITIONS BASED ON PROLINE DERIVATIVES AND USES THEREOF |
| KR20160068177A (en) | 2014-12-05 | 2016-06-15 | 코웨이 주식회사 | Cosmetic Composition Including Nano-Carrier With Myristyl 3-Glyceryl Ascorbate |
| CN110812267A (en) * | 2019-11-15 | 2020-02-21 | 上海应用技术大学 | A kind of soybean isoflavone liposome and preparation method thereof |
| KR102081180B1 (en) | 2019-08-14 | 2020-02-25 | 한국콜마주식회사 | Elastic liposome composition comprising sucrose based surfactant, and cosmetic composition containing the same |
| KR20200049196A (en) * | 2018-10-31 | 2020-05-08 | (주)아모레퍼시픽 | oil-in-water composition with high emulsion stability |
| JP2022043328A (en) * | 2017-06-02 | 2022-03-15 | 味の素株式会社 | Composition having vesicle containing acylproline |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102067094B1 (en) | 2018-04-17 | 2020-01-15 | 김철환 | A surfactant-free type oil-water dispersion composition, surfactant-free type water-oil dispersion composition and the manufacturing method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202126A (en) * | 1987-08-20 | 1993-04-13 | Parfums Christian Dior | Composition containing pregnenolone or a pregnenolone ester incorporated in liposomes, and a method for regenerating, or revitalizing the skin therewith |
| FR2619711B1 (en) * | 1987-09-02 | 1991-01-11 | Givaudan La Virotte Cie Ets | COSMETIC APPLICATION OF PROLINE DERIVATIVES, HYDROXYPROLINE AND / OR MIXTURE OF AMINO ACIDS RESULTING FROM COLLAGEN HYDROLYSIS |
| GB9007356D0 (en) * | 1990-04-02 | 1990-05-30 | Pawliszyn Janusz B | Micro solid phase extraction with fused silica optical fibres |
| JP2999301B2 (en) * | 1991-07-25 | 2000-01-17 | 協和醗酵工業株式会社 | Cosmetics |
| JP3271840B2 (en) * | 1993-12-06 | 2002-04-08 | 花王株式会社 | Novel isoflavone glycosides and cosmetics containing the same |
| KR100483391B1 (en) * | 1998-01-16 | 2005-04-15 | 칼라 액세스, 인크. | Stabilized Whitening Compositions and Method of Preparing Same |
| GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| KR100836035B1 (en) * | 2002-02-19 | 2008-06-09 | (주)아모레퍼시픽 | Saturated and unsaturated lecithin-containing nanoemulsions and cosmetic compositions containing the same |
-
2002
- 2002-05-02 KR KR10-2002-0024250A patent/KR100482355B1/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2894828A1 (en) * | 2005-12-21 | 2007-06-22 | Jean Alexis Grimaud | NEW COSMETOLOGICAL AND / OR DERMATOLOGICAL COMPOSITIONS BASED ON PROLINE DERIVATIVES AND USES THEREOF |
| WO2007072178A1 (en) * | 2005-12-21 | 2007-06-28 | Texinfine | Novel proline-derivative based cosmetological and/or dermatological compositions and uses thereof |
| KR20160068177A (en) | 2014-12-05 | 2016-06-15 | 코웨이 주식회사 | Cosmetic Composition Including Nano-Carrier With Myristyl 3-Glyceryl Ascorbate |
| JP2022043328A (en) * | 2017-06-02 | 2022-03-15 | 味の素株式会社 | Composition having vesicle containing acylproline |
| KR20200049196A (en) * | 2018-10-31 | 2020-05-08 | (주)아모레퍼시픽 | oil-in-water composition with high emulsion stability |
| KR102081180B1 (en) | 2019-08-14 | 2020-02-25 | 한국콜마주식회사 | Elastic liposome composition comprising sucrose based surfactant, and cosmetic composition containing the same |
| CN110812267A (en) * | 2019-11-15 | 2020-02-21 | 上海应用技术大学 | A kind of soybean isoflavone liposome and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100482355B1 (en) | 2005-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7412838B2 (en) | Cosmetic composition containing particles containing high ceramide content and method for producing the same | |
| JP6231624B2 (en) | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected | |
| KR101934208B1 (en) | Compositions for Moisturizing Skin Containing Vegetable Vernix Ingredients | |
| KR101867847B1 (en) | O/W Emulsion having recrystallized particle and Cosmetic composition comprising thereof | |
| JP2019535783A (en) | Composition comprising truffle extract and neohesperidin dihydrochalcone | |
| KR20080106618A (en) | Multi-emulsifying vesicles comprising multilayer liposomes and single membrane nano liposomes | |
| KR101176523B1 (en) | A Cosmetic Composition having phase transformation | |
| KR20150044104A (en) | Makeup kit composition having double layer of makeup layer and moisture and shimmering layer after applying on skin | |
| KR20110078955A (en) | Cosmetic composition containing MBC as an active ingredient | |
| KR100482355B1 (en) | Liposome or nanoemulsion containing dipalmitoyl hydroxyproline and soy isoflavone and a cosmetic composition containing the liposome and/or the nanoemulsion and method thereof | |
| EP2120844A2 (en) | Skin lightening composition for hyperpigmented skin | |
| KR20160082054A (en) | Emulsifier-Free Cosmetic Composition of the Oil-in-Water Emulsion Type and Preparation Method Thereof | |
| JP2025085824A (en) | Composition for external use containing azelaic acid and its manufacturing method | |
| KR20050091162A (en) | Methods for manufacturing nanoemulsion and liposomes containing vitamin a, b, c, e and their derivatives and cosmetics containing it | |
| KR20150072040A (en) | Cosmetic composition including nano-carrier with dipalmitohydroxyproline | |
| KR20150081932A (en) | Oil-in-water type emulsion composition and method for preparing thereof | |
| KR102142960B1 (en) | Process for preparing nano-liposome using horse fat and nanodiamon, and compositions comprising the same | |
| KR100858626B1 (en) | Cosmetic composition for lip protection containing ceramide and synthetic palmitoylpentapeptide as active ingredients | |
| KR20100044357A (en) | Anti-aging cosmetic composition containing rosmarinic acid encapsulated in nanoliposome | |
| KR100501309B1 (en) | Manufacturing Method of Nano-emulsified Cosmetic Composition Containing Arbutin | |
| KR102281403B1 (en) | Cosmetic composition for improving skin wrinkles containing Torreya nucifera ceramide and extracts of Curcuma and defatted camellia seeds | |
| KR102594145B1 (en) | Nanoemulsion of translucent formulation containing natural ceramide and manufacturing method thereof and manufacturing method of customized cosmetics including the same | |
| KR20090115478A (en) | Cosmetic composition containing nanosomes stabilized by inclusion of stem cell culture products | |
| KR102672909B1 (en) | Cosmetic composition for external application for skin comprising Palmarosa oil and aroma composition as an active ingredient | |
| JP3658114B2 (en) | Topical skin preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20020502 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040729 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050317 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050331 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050331 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20080306 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090401 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100330 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110401 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment | ||
| PR1001 | Payment of annual fee |
Payment date: 20120402 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment | ||
| PR1001 | Payment of annual fee |
Payment date: 20130402 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140331 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150316 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150316 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160325 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160325 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20170309 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170309 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20180403 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180403 Start annual number: 14 End annual number: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20190319 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190319 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200228 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210318 Start annual number: 17 End annual number: 17 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220324 Start annual number: 18 End annual number: 18 |
|
| PC1801 | Expiration of term |